Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Swissmedic

- PMLiVE

Pfizer/BioNTech’s second bivalent COVID-19 booster approved by MHRA

The adapted vaccine targets the original virus and Omicron BA.4 and BA.5 strains

- PMLiVE

Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

A phase 3 trial showed significantly longer time to flare for both JPsA and ERA patients

- PMLiVE

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations

- PMLiVE

Pfizer/BioNTech BA.1 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Moderna’s Omicron BA.1 targeting bivalent booster recommended by CHMP for use in EU

Results from a phase 2/3 trial demonstrated mRNA-1273.214 had superior neutralising antibody response against Omicron compared to the currently authorised booster

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

Data from an ongoing phase 3 paediatric trial demonstrated Nuvaxovid produced 80% clinical efficacy in this age group

- PMLiVE

Moderna’s Omicron booster receives MHRA approval

The booster dose can be used in adults aged 18 years and over to protect against contracting COVID-19

- PMLiVE

Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer

The approval for the treatment applies to England, Scotland and Wales

- PMLiVE

MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug

Oxybryta is the first treatment in Britain to directly block sickle haemoglobin polymerisation

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

Connecting Diverse Communities to Elevate Healthcare

Dvorah Richler, Head of Soaring with Roche, and Michael Duong, Head of Innovation at Michael Duong, discuss the 5 healthcare challenges that Soaring with Roche aims to solve through innovative...

Impetus Digital

- PMLiVE

AbbVie’s Crohn’s disease drug given green light by MHRA

An estimated 217,000 people aged 16 and over live with the condition in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links